SE0301882D0 - New use I - Google Patents

New use I

Info

Publication number
SE0301882D0
SE0301882D0 SE0301882A SE0301882A SE0301882D0 SE 0301882 D0 SE0301882 D0 SE 0301882D0 SE 0301882 A SE0301882 A SE 0301882A SE 0301882 A SE0301882 A SE 0301882A SE 0301882 D0 SE0301882 D0 SE 0301882D0
Authority
SE
Sweden
Prior art keywords
wound healing
new use
promoting wound
inhibitor
mammal
Prior art date
Application number
SE0301882A
Other languages
English (en)
Swedish (sv)
Inventor
Cecilia Nilsson
Catrine Nilsson
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0301882A priority Critical patent/SE0301882D0/xx
Publication of SE0301882D0 publication Critical patent/SE0301882D0/xx
Priority to PCT/SE2004/000996 priority patent/WO2004112784A1/en
Priority to CA002529406A priority patent/CA2529406A1/en
Priority to KR1020057024626A priority patent/KR20060023570A/ko
Priority to JP2006517048A priority patent/JP2007521264A/ja
Priority to AU2004249099A priority patent/AU2004249099A1/en
Priority to CNA2004800177434A priority patent/CN1812784A/zh
Priority to EP04749034A priority patent/EP1638553A1/en
Priority to NO20060416A priority patent/NO20060416L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SE0301882A 2003-06-25 2003-06-25 New use I SE0301882D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0301882A SE0301882D0 (sv) 2003-06-25 2003-06-25 New use I
PCT/SE2004/000996 WO2004112784A1 (en) 2003-06-25 2004-06-21 New use i
CA002529406A CA2529406A1 (en) 2003-06-25 2004-06-21 New use i
KR1020057024626A KR20060023570A (ko) 2003-06-25 2004-06-21 새로운 용도 ｉ
JP2006517048A JP2007521264A (ja) 2003-06-25 2004-06-21 新規用途ｉ
AU2004249099A AU2004249099A1 (en) 2003-06-25 2004-06-21 New use I
CNA2004800177434A CN1812784A (zh) 2003-06-25 2004-06-21 新用途i
EP04749034A EP1638553A1 (en) 2003-06-25 2004-06-21 New use i
NO20060416A NO20060416L (no) 2003-06-25 2006-01-25 Ny anvendelse I

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301882A SE0301882D0 (sv) 2003-06-25 2003-06-25 New use I

Publications (1)

Publication Number Publication Date
SE0301882D0 true SE0301882D0 (sv) 2003-06-25

Family

ID=27656617

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301882A SE0301882D0 (sv) 2003-06-25 2003-06-25 New use I

Country Status (9)

Country Link
EP (1) EP1638553A1 (xx)
JP (1) JP2007521264A (xx)
KR (1) KR20060023570A (xx)
CN (1) CN1812784A (xx)
AU (1) AU2004249099A1 (xx)
CA (1) CA2529406A1 (xx)
NO (1) NO20060416L (xx)
SE (1) SE0301882D0 (xx)
WO (1) WO2004112784A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE417837T1 (de) 2004-05-24 2009-01-15 Amgen Inc Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
AU2006316867A1 (en) 2005-11-22 2007-05-31 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
JP5098011B2 (ja) * 2006-11-20 2012-12-12 国立大学法人山口大学 創傷治癒促進剤
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2523196T3 (es) * 2007-07-13 2014-11-21 Icagen, Inc. Inhibidores de los canales de sodio
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103204824B (zh) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN105061288B (zh) * 2015-08-07 2017-09-15 武汉华素康生物科技有限公司 化合物及其制备方法和应用
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN118340765B (zh) * 2024-04-30 2024-08-23 广州市朝利良生物科技有限公司 苯甲酰胺类化合物在制备促伤口愈合药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH10639A (en) * 1967-07-17 1977-07-22 Research Corp Method of treatment and composition containing silver sulfadiazine
TR199701096T1 (xx) * 1995-04-04 1998-02-21 Texas Biotechnology Corporation Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri.
ATE229949T1 (de) * 1996-10-16 2003-01-15 American Cyanamid Co Herstellung und verwendung von ortho-sulfonamido- heteroarylhydroxamsäuren als matrix- metalloproteinase und tace inhibitoren
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds

Also Published As

Publication number Publication date
NO20060416L (no) 2006-03-24
KR20060023570A (ko) 2006-03-14
JP2007521264A (ja) 2007-08-02
CN1812784A (zh) 2006-08-02
AU2004249099A1 (en) 2004-12-29
CA2529406A1 (en) 2004-12-29
WO2004112784A1 (en) 2004-12-29
EP1638553A1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
SE0301882D0 (sv) New use I
SE0301886D0 (sv) New use V
SE0301888D0 (sv) New use VII
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
SE0101387D0 (sv) Novel compounds
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
MX2007005408A (es) Compuestos de aminoquinazolinas.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
NO20083032L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
ATE384058T1 (de) Thiazolderivate
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MXPA05010020A (es) Derivados de oxamida.
SE0301883D0 (sv) New use II
SE0004101D0 (sv) New use
SE0301885D0 (sv) New use IV
SE0301884D0 (sv) New use III
SE0002739D0 (sv) New use
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente